/**/ RNS Number : 0655P IQ-AI Limited 20 May 2024   May 20, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics Announces Second U.S. FDA Rare Pediatric Disease Designation Granted to GaM   For the Treatment of Pediatric-Type Diffuse High Grade Glioma (“HGG”) Further to the announcements made on 8 November 2023 and

/**/ RNS Number : 8182O IQ-AI Limited 17 May 2024   May 17, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe AG   Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces the successful deployment of its state-of-the-art software

/**/ RNS Number : 9596N IQ-AI Limited 10 May 2024   May 10, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics Announces U.S. FDA Rare Pediatric Disease Designation Granted to GaM   For the Treatment of atypical teratoid rhabdoid tumor (“ATRT”) Further to the announcement made on 8 November 2023, Imaging Biometrics (“IB”),

/**/ RNS Number : 0442N IQ-AI Limited 02 May 2024   IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics Announces Expanded Access Program for Oral Gallium Maltolate Company initiating program based on phase 1 tolerability and safety results   Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has received

/**/ RNS Number : 4602M IQ-AI Limited 29 April 2024   IQ-AI Ltd (“IQ-AI” or the “Company”) Publication of Annual Report   The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2023.   The Annual Report will be available on the Company’s corporate website

/**/ RNS Number : 5260F IQ-AI Limited 05 March 2024   IQ-AI Limited (“IQ-AI” or the “Company”) Grant of Options   IQAI Limited (the “Company” or “IQAI”), announces that, the Company has granted options over a total of 18,905,474 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) to the Directors and employees to the

– Article source

/**/ RNS Number : 2468F IQ-AI Limited 01 March 2024   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares

/**/ RNS Number : 2390F IQ-AI Limited 01 March 2024   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares

/**/ RNS Number : 3536E IQ-AI Limited 26 February 2024   IQ-AI Limited (“IQ-AI” or the “Company”) Result of Broker Option and Total Voting Rights   IQAI Limited (the “Company” or “IQAI”), is pleased to announce the result of the Broker Option that was announced on 22 February 2024 alongside a £300,000 placing.   The Company’s broker,